Evidence map›Paper›PMID 36298791›Full record

ArticleViruses2022

Susceptibility to Resurgent COVID-19 Outbreaks Following Vaccine Rollouts: A Modeling Study.

Georgios Neofotistos, Mattia Angeli, Marios Mattheakis, Efthimios Kaxiras

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Georgios NeofotistosHarvard J. A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-5929-7337
Mattia AngeliHarvard J. A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0002-1875-8165
Marios MattheakisHarvard J. A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-6450-1128
Efthimios KaxirasHarvard J. A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0002-4682-0165
Harvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Using the recently proposed Susceptible-Asymptomatic-Infected-Vaccinated-Removed (SAIVR) model, we study the impact of key factors affecting COVID-19 vaccine rollout effectiveness and the susceptibility to resurgent epidemics. The SAIVR model expands the widely used Susceptible-Infectious-Removed (SIR) model for describing epidemics by adding compartments to include the asymptomatic infected (A) and the vaccinated (V) populations. We solve the model numerically to make predictions on the susceptibility to resurgent COVID-19 epidemics depending on initial vaccination coverage, importation loads, continuing vaccination, and more contagious SARS-CoV-2 variants, under persistent immunity and immunity waning conditions. The parameters of the model represent reported epidemiological characteristics of the SARS-CoV-2 virus such as the disease spread in countries with high levels of vaccination coverage. Our findings help explain how the combined effects of different vaccination coverage levels and waning immunity lead to distinct patterns of resurgent COVID-19 epidemics (either surges or endemic), which are observed in countries that implemented different COVID-19 health policies and achieved different vaccinated population plateaus after the vaccine rollouts in the first half of 2021.

Indexed as

COVID-19Influenza VaccinesCOVID-19 VaccinesDisease OutbreaksHumansSARS-CoV-2VaccinationCOVID-19 VaccinesInfluenza Vaccinescompartmental modelCOVID-19 vaccinesresurgent epidemicsSARS-CoV-2vaccination coveragewaning immunity

Identifiers

PMID36298791
PMCPMC9608598
OpenAlexW4304782255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.